Latest Insider Transactions at Generation Bio Co. (GBIO)
This section provides a real-time view of insider transactions for Generation Bio Co. (GBIO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Generation Bio Co. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Generation Bio Co.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 15
2022
|
Geoff Mcdonough PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
46,876
+3.69%
|
-
|
|
Jul 15
2022
|
Douglas Kerr CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,367
-1.27%
|
$30,569
$7.18 P/Share
|
|
Jul 15
2022
|
Douglas Kerr CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,876
+4.15%
|
-
|
|
Jul 15
2022
|
Matthew Norkunas CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,367
-29.36%
|
$30,569
$7.18 P/Share
|
|
Jul 15
2022
|
Matthew Norkunas CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,876
+50.0%
|
-
|
|
Jul 15
2022
|
Antoinette Paone CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,422
-24.56%
|
$16,954
$7.18 P/Share
|
|
Jul 15
2022
|
Antoinette Paone CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,250
+45.55%
|
-
|
|
Jul 15
2022
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,367
-2.05%
|
$30,569
$7.18 P/Share
|
|
Jul 15
2022
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,876
+6.53%
|
-
|
|
Jul 15
2022
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,367
-29.36%
|
$30,569
$7.18 P/Share
|
|
Jul 15
2022
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,876
+50.0%
|
-
|
|
Mar 10
2022
|
Donald William Nicholson |
BUY
Open market or private purchase
|
Direct |
8,126
+6.68%
|
$32,504
$4.71 P/Share
|
|
Mar 09
2022
|
Donald William Nicholson |
BUY
Open market or private purchase
|
Direct |
2,293
+2.13%
|
$9,172
$4.79 P/Share
|
|
Oct 28
2021
|
Anthony G. Quinn |
BUY
Bona fide gift
|
Indirect |
72,837
+50.0%
|
-
|
|
Oct 28
2021
|
Anthony G. Quinn |
SELL
Bona fide gift
|
Direct |
72,837
-100.0%
|
-
|
|
Sep 29
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
30
-4.7%
|
$720
$24.59 P/Share
|
|
Sep 29
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
16,556
-100.0%
|
$397,344
$24.59 P/Share
|
|
Sep 29
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
16,586
-52.35%
|
$398,064
$24.59 P/Share
|
|
Sep 28
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
24
-3.63%
|
$600
$25.24 P/Share
|
|
Sep 28
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
13,089
-44.15%
|
$327,225
$25.24 P/Share
|
|
Sep 28
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
13,113
-23.89%
|
$327,825
$25.24 P/Share
|
|
Sep 27
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
95
-12.55%
|
$2,375
$25.7 P/Share
|
|
Sep 27
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
51,294
-63.37%
|
$1,282,350
$25.7 P/Share
|
|
Sep 27
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
51,389
-37.96%
|
$1,284,725
$25.7 P/Share
|
|
Sep 24
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
54
-6.66%
|
$1,350
$25.84 P/Share
|
|
Sep 24
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
28,862
-26.29%
|
$721,550
$25.84 P/Share
|
|
Sep 24
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
28,916
-16.47%
|
$722,900
$25.84 P/Share
|
|
Sep 23
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
140
-14.72%
|
$3,640
$26.13 P/Share
|
|
Sep 23
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
75,325
-20.34%
|
$1,958,450
$26.34 P/Share
|
|
Sep 23
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
75,465
-18.47%
|
$1,962,090
$26.27 P/Share
|
|
Sep 22
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
57
-5.65%
|
$1,425
$25.89 P/Share
|
|
Sep 22
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
30,560
-14.17%
|
$764,000
$25.89 P/Share
|
|
Sep 22
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
30,617
-9.91%
|
$765,425
$25.89 P/Share
|
|
Sep 17
2021
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
100,000
-7.89%
|
-
|
|
Sep 17
2021
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,000,000
-12.33%
|
-
|
|
Sep 14
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
4,500
-2.22%
|
$126,000
$28.07 P/Share
|
|
Sep 14
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+2.17%
|
$18,000
$4.59 P/Share
|
|
Sep 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
3,000
-0.75%
|
$78,000
$26.22 P/Share
|
|
Sep 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+1.47%
|
$12,000
$4.59 P/Share
|
|
Aug 23
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.75%
|
$37,500
$25.04 P/Share
|
|
Aug 23
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$6,000
$4.59 P/Share
|
|
Aug 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.25%
|
$34,500
$23.24 P/Share
|
|
Aug 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$6,000
$4.59 P/Share
|
|
Jul 12
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
3,000
-0.75%
|
$72,000
$24.96 P/Share
|
|
Jul 12
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+1.47%
|
$12,000
$4.59 P/Share
|
|
Jul 08
2021
|
Douglas Kerr CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,518
-0.53%
|
$87,950
$25.19 P/Share
|
|
Jul 08
2021
|
Douglas Kerr CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,518
+1.05%
|
$17,590
$5.16 P/Share
|
|
Jun 24
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
58
-4.4%
|
$1,508
$26.08 P/Share
|
|
Jun 24
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
30,950
-93.39%
|
$804,700
$26.08 P/Share
|
|
Jun 24
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
31,008
-48.9%
|
$806,208
$26.08 P/Share
|